Navigation Links
Generex Announces $3.0 Million Capital Investment
Date:1/25/2011

per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance.  In addition, with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each warrant will be increased or decreased proportionately, so that after such adjustment the aggregate warrant exercise price payable for the adjusted number of shares issuable upon exercise will be the same as the aggregate warrant exercise price in effect immediately prior to such adjustment.

Generex intends to use the net proceeds from the offering for general corporate purposes which will include, inter alia, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications, and general working capital.

The closing of the offering is expected to take place on or about January 25, 2011, subject to the satisfaction of customary closing conditions.

Seahawk Capital Partners, Inc. was paid a finders' fee by the Company in connection with this offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  Generex is offering these securities pursuant to an effective shelf registration statement and only by prospectus.  Copies of the final prospectus supplement in respect of the offering, together with the accompanying base prospectus, can be obtained at the Securities and Exchange Commission's website at http://www.sec.gov.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Additional Details for October 21st Live Video Webcast
2. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
3. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
4. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
5. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
6. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
7. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
10. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
11. Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... According to the 2013 Raw Material ... look and feel of markets for raw materials and ... will push for more branded, science-backed products.” , Natural ... market growth in the last decade as consumers increasingly ... cosmetics to fit a more ‘wellness’ lifestyle approach. ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... of Arpida Ltd (SWX: ARPN) has approved the proposals ... A total of 73 shareholders were present at the ... represented, or 29.3% of the total,number of shares issued ... 1. Approval of the 2007 Business Report, Company ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... announced it will,report results for its first quarter 2008 ... A conference call to review the results will begin ... 2008 and will be hosted by Anthony DiTonno,President and ...
... cell company,Neuralstem, Inc. (Amex: CUR ) is filing ... StemCells intentionally withheld crucial,information highly material to the patentability ... this was done with the intent to deceive,the United ... patent allowed. As,a result of these actions, Neuralstem is ...
Cached Biology Technology:Arpida Annual General Meeting of Shareholders Approves All Board Proposals 2NeurogesX to Report First Quarter 2008 Financial Results 2NeurogesX to Report First Quarter 2008 Financial Results 3Neuralstem Sues StemCells, Inc. Over New Patent 2Neuralstem Sues StemCells, Inc. Over New Patent 3
(Date:8/27/2014)... group of fish began exploring land and evolved into tetrapods ... these ancient fish used their fishy bodies and fins in ... remain scientific mysteries. , Researchers at McGill University published ... fish, called Polypterus , to help show what might ... the water. Polypterus is an African fish that ...
(Date:8/27/2014)... is easier when it is related to ability that ... learn a new melody more easily than learning how ... the Center for the Neural Basis of Cognition (CNBC)a ... Mellon Universityhave discovered a fundamental constraint in the brain ... cover story in the Aug. 28, 2014, issue of ...
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3University of Utah biologist wins Turkey's top science prize 2
... can aid forensics teams in determining if a person ... June issue of Radiology. , MDCT is comparable to ... are indicative of drowning. , "Our findings show ... reduce the need for conventional autopsy when drowning is ...
... H5N1 strain of avian influenza may hold the key to ... of researchers. In a study published today in the open ... antibodies taken from avian flu survivors in Vietnam can be ... virus in culture vitro and in mice. , The H5N1 ...
... researchers have uncovered the basis by which pregnant women ... the HIV virus works to counteract this defence. The ... in malaria-ravished regions. , Malaria is a parasitic disease ... people every year. While the disease affects mostly children, ...
Cached Biology News:'Virtual autopsy' helps identify drowning as cause of death 2Avian influenza survivors' antibodies effective at neutralising H5N1 strain 2HIV and malaria combine to adversely affect pregnant women and their infants 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: